NCT00420355View on ClinicalTrials.gov

Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients

PHASE4TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

September 30, 2008

Conditions
HIV Infection
Interventions
DRUG

atazanavir

Atazanavir 300 mg daily on Days 6-12.

DRUG

lopinavir/ritonavir

Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.

Trial Locations (1)

73104

OUHSC General Clinical Research Center, Oklahoma City

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

University of Oklahoma

OTHER